These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32576219)

  • 1. Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study).
    Paller AS; Browning J; Nikolic M; Bodemer C; Murrell DF; Lenon W; Krusinska E; Reha A; Lagast H; Barth JA;
    Orphanet J Rare Dis; 2020 Jun; 15(1):158. PubMed ID: 32576219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study.
    Murrell DF; Paller AS; Bodemer C; Browning J; Nikolic M; Barth JA; Lagast H; Krusinska E; Reha A;
    Orphanet J Rare Dis; 2020 Jul; 15(1):190. PubMed ID: 32693833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Birch Bark Extract: A Review in Epidermolysis Bullosa.
    Heo YA
    Drugs; 2023 Sep; 83(14):1309-1314. PubMed ID: 37658982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.
    Kern JS; Sprecher E; Fernandez MF; Schauer F; Bodemer C; Cunningham T; Löwe S; Davis C; Sumeray M; Bruckner AL; Murrell DF;
    Br J Dermatol; 2023 Jan; 188(1):12-21. PubMed ID: 36689495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oleogel-S10 Phase 3 study "EASE" for epidermolysis bullosa: study design and rationale.
    Kern JS; Schwieger-Briel A; Löwe S; Sumeray M; Davis C; Martinez AE
    Trials; 2019 Jun; 20(1):350. PubMed ID: 31186047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oleogel-S10 in Dystrophic Epidermolysis Bullosa: A Case Series Evaluating the Impact on Wound Burden Over Two Years.
    Torres Pradilla M; Álvarez E; Novoa M; Lozano I; Trujillo M
    Adv Ther; 2024 Feb; 41(2):867-877. PubMed ID: 38170434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial.
    Guttmann-Gruber C; Piñón Hofbauer J; Tockner B; Reichl V; Klausegger A; Hofbauer P; Wolkersdorfer M; Tham KC; Lim SS; Common JE; Diem A; Ude-Schoder K; Hitzl W; Lagler F; Reichelt J; Bauer JW; Lang R; Laimer M
    Orphanet J Rare Dis; 2021 Nov; 16(1):473. PubMed ID: 34749770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
    Guide SV; Gonzalez ME; Bağcı IS; Agostini B; Chen H; Feeney G; Steimer M; Kapadia B; Sridhar K; Quesada Sanchez L; Gonzalez F; Van Ligten M; Parry TJ; Chitra S; Kammerman LA; Krishnan S; Marinkovich MP
    N Engl J Med; 2022 Dec; 387(24):2211-2219. PubMed ID: 36516090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group.
    Spruance SL; Rea TL; Thoming C; Tucker R; Saltzman R; Boon R
    JAMA; 1997 May; 277(17):1374-9. PubMed ID: 9134943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
    Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF
    J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.
    Woodley DT; Cogan J; Hou Y; Lyu C; Marinkovich MP; Keene D; Chen M
    J Clin Invest; 2017 Aug; 127(8):3028-3038. PubMed ID: 28691931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
    Feinstein JA; Jambal P; Peoples K; Lucky AW; Khuu P; Tang JY; Lara-Corrales I; Pope E; Wiss K; Hook KP; Levin LE; Morel KD; Paller AS; McCuaig CC; Powell J; Eichenfield LF; Price H; Levy ML; Schachner LA; Browning JC; Bayliss S; Jahnke M; Shwayder T; Glick SA; Bruckner AL
    JAMA Dermatol; 2019 Feb; 155(2):196-203. PubMed ID: 30586139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of biocellulose, carboxymethyl cellulose and normal saline dressing in epidermolysis bullosa.
    Dwiyana RF; Yogya Y; Gondokaryono SP; Diana IA; Suwarsa O; Ramali LM; Sutedja EK; Rahardja JI; Gunawan H
    J Wound Care; 2019 Oct; 28(Sup10):S4-S9. PubMed ID: 31600103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Cutaneous Manifestations of Genetic Epidermolysis Bullosa: A Multiple Case Series.
    Miura Y; Nakagomi S
    J Wound Ostomy Continence Nurs; 2021 Sep-Oct 01; 48(5):453-459. PubMed ID: 34495939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex.
    So JY; Fulchand S; Wong CY; Li S; Nazaroff J; Gorell ES; de Souza MP; Murrell DF; Teng JM; Chiou AS; Tang JY
    Orphanet J Rare Dis; 2022 Jul; 17(1):270. PubMed ID: 35841105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial.
    Petrof G; Martinez-Queipo M; Mellerio JE; Kemp P; McGrath JA
    Br J Dermatol; 2013 Nov; 169(5):1025-33. PubMed ID: 24032424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
    Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
    Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin cleansing and topical product use in patients with epidermolysis bullosa: Results from a multicenter database.
    Shayegan LH; Levin LE; Galligan ER; Lucky AW; Bruckner AL; Pope E; Lara-Corrales I; Wiss K; McCuaig CC; Garzon MC; Eichenfield LF; Hook KP; Browning JC; Schachner LA; Perman MJ; Castelo-Soccio L; Levy ML; Glick SA; Morel KD
    Pediatr Dermatol; 2020 Mar; 37(2):326-332. PubMed ID: 31944391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical sucralfate cream treatment for aplasia cutis congenita with dystrophic epidermolysis bullosa: a case study.
    Yaşar Ş; Yaşar B; Cebeci F; Bayoğlu D; Nuhoğlu Ç
    J Wound Care; 2018 Nov; 27(11):768-771. PubMed ID: 30398936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.